Currently, Matinas Biopharma Holdings Inc [MTNB] is trading at $0.24, up 7.35%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MTNB shares have gain 9.02% over the last week, with a monthly amount glided 21.52%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, February 2024, Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis. In a post published today on Yahoo Finance, ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options.
From an analyst’s perspective:
Matinas Biopharma Holdings Inc [AMEX: MTNB] stock has seen the most recent analyst activity on May 11, 2021, when Piper Sandler downgraded its rating to a Neutral. On January 27, 2020, Piper Sandler initiated with a Overweight rating and assigned a price target of $3 on the stock. SunTrust started tracking the stock assigning a Buy rating. SunTrust initiated its recommendation with a Buy. Aegis Capital started tracking with a Buy rating for this stock on January 09, 2020, and assigned it a price target of $3.50. In a note dated June 26, 2019, H.C. Wainwright initiated an Buy rating and provided a target price of $4 on this stock.
This stock has fluctuated between a low of $0.11 and a high of $0.89 over the last 52 weeks. Matinas Biopharma Holdings Inc [AMEX: MTNB] shares were valued at $0.24 at the most recent close of the market.
Analyzing the MTNB fundamentals
Trailing Twelve Months sales for Matinas Biopharma Holdings Inc [AMEX:MTNB] were 2.16M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2263 points at the first support level, and at 0.2131 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2513, and for the 2nd resistance point, it is at 0.2631.
Matinas Biopharma Holdings Inc [MTNB] reported earnings per share of -$0.03 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.03/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.03 per share as compared to estimates of -$0.03 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Matinas Biopharma Holdings Inc [AMEX:MTNB] is 6.19. In addition, the Quick Ratio stands at 6.19 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 24.08, the price to book ratio is 2.25.
